Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

Por Clemow, David B., Nyhuis, Allen W., Robinson, Rebecca L.
Publicado no CNS Neurosci Ther (2016)

Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study

Por Adler, Lenard A., Clemow, David B., Williams, David W., Durell, Todd M.
Publicado em 2014

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

Por Clemow, David B, Bushe, Chris, Mancini, Michele, Ossipov, Michael H, Upadhyaya, Himanshu
Publicado no Neuropsychiatr Dis Treat (2017)

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder

Por Kabul, Samaneh, Alatorre, Carlos, Montejano, Leslie B., Farr, Amanda M., Clemow, David B.
Publicado no CNS Neurosci Ther (2015)

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled,...

Por Wietecha, Linda A., Clemow, David B., Buchanan, Andrew S., Young, Joel L., Sarkis, Elias H., Findling, Robert L.
Publicado no CNS Neurosci Ther (2016)

Lasmiditan mechanism of action – review of a selective 5-HT(1F) agonist

Por Clemow, David B., Johnson, Kirk W., Hochstetler, Helen M., Ossipov, Michael H., Hake, Ann M., Blumenfeld, Andrew M.
Publicado no J Headache Pain (2020)